Alcon Inc. (ALC)
NYSE: ALC · Real-Time Price · USD
91.38
-1.16 (-1.25%)
Apr 21, 2025, 4:00 PM EDT - Market closed
Alcon Revenue
In the year 2024, Alcon had annual revenue of $9.91B with 4.82% growth. Alcon had revenue of $2.50B in the quarter ending December 31, 2024, with 6.38% growth.
Revenue (ttm)
$9.91B
Revenue Growth
+4.82%
P/S Ratio
4.59
Revenue / Employee
$387,164
Employees
25,599
Market Cap
45.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.91B | 456.00M | 4.82% |
| Dec 31, 2023 | 9.46B | 738.00M | 8.47% |
| Dec 31, 2022 | 8.72B | 426.00M | 5.14% |
| Dec 31, 2021 | 8.29B | 1.46B | 21.34% |
| Dec 31, 2020 | 6.83B | -675.00M | -8.99% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ALC News
- 18 days ago - Alcon Publishes Agenda for 2025 Annual General Meeting - Business Wire
- 20 days ago - Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter - Business Wire
- 26 days ago - Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease - Business Wire
- 26 days ago - LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR - Business Wire
- 4 weeks ago - Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities - Business Wire
- 4 weeks ago - Alcon Agrees to Acquire LENSAR, Inc. - Business Wire
- 4 weeks ago - Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss - GlobeNewsWire
- 5 weeks ago - Alcon to Host 2025 Capital Markets Day - Business Wire